Resolution of chronic hepatitis delta infection after five years of peginterferon–adefovir: Lessons from a case report - 06/06/13
, Mashiko Setshedi b, Christophe Renou c
Corresponding author. Tel.: +33 1 48 95 75 96; fax: +33 1 48 95 59 11.Summary |
There is still some controversy about the treatment of hepatitis delta virus (HDV) infection and the treatment endpoints. A 48-year-old patient was treated with a combination of peginterferon-⍺ and adefovir, and HDV RNA clearance occurred after 3years of treatment. However, treatment was continued until HBs antigen (Ag) seroconversion, which occurred after 5years of therapy. Oneyear after the end of the treatment, the patient was still HBs Ag and HDV RNA negative. This case report suggests that combined peginterferon-⍺ and adefovir may be effective in treating HDV infection and, if given over a longer period, may result in hepatitis B surface antigen (HBsAg) seroconversion. It highlights the interest of using HBsAg quantification associated with a sensitive RT-PCR approach for monitoring the treatment of chronic hepatitis delta. HBsAg seroconversion, or at least significant decrease, could be a more relevant endpoint than HDV RNA undetectability for discontinuing HDV treatment and preventing the occurrence of virological relapses.
Le texte complet de cet article est disponible en PDF.Plan
Vol 37 - N° 3
P. e81-e84 - juin 2013 Retour au numéro
Article précédent
- Regional portal hypertension, systemic lymphadenopathy, and splenomegaly associated with autoimmune pancreatitis
- Xiaofei Cheng, Dongkai Zhou, Jianfeng Wei, Shusen Zheng
- Liver endometriosis presenting as a liver mass associated with high blood levels of tumoral biomarkers
- Ahmed Fouad Bouras, André Vincentelli, Emmanuel Boleslawski, Stéphanie Truant, Guido Liddo, Alain Prat, François-René Pruvot, Philippe Zerbib
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?